Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Gamida Cell Ltd.
  6. Summary
    GMDA   IL0011552663

GAMIDA CELL LTD.

(GMDA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
2.76(c) 2.7(c) 2.56(c) 2.37(c) 2.41 Last
300 762 443 716 712 926 627 576 790 174 Volume
+0.73% -2.17% -5.19% -7.42% +1.69% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -84,8 M - -
Net cash position 2021 21,2 M - -
P/E ratio 2021 -1,65x
Yield 2021 -
Sales 2022 3,07 M - -
Net income 2022 -123 M - -
Net Debt 2022 111 M - -
P/E ratio 2022 -1,21x
Yield 2022 -
Capitalization 141 M 141 M -
EV / Sales 2021 -
EV / Sales 2022 81,8x
Nbr of Employees 111
Free-Float 72,0%
More Financials
Company
Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology to develop a pipeline of products designed to address the limitations of cell therapies. The following are the Company's clinical pipeline products:... 
Sector
Biotechnology & Medical Research
Calendar
12/06 | 10:00amPresentation
More about the company
Ratings of Gamida Cell Ltd.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about GAMIDA CELL LTD.
11/25SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors Gamida C..
PR
11/24Gamida Cell Ltd. Announces Resignation of David Fox from the Board of Directors
CI
11/16Needham Adjusts Price Target on Gamida Cell to $12 from $14, Keeps Buy Rating
MT
11/16Oppenheimer Adjusts Gamida Cell PT to $15 From $17, Maintains Outperform Rating
MT
11/16Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
BU
11/15SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors Gamida C..
PR
11/15GAMIDA CELL : Reports Third Quarter 2021 Financial Results and Provides Company Update - F..
PU
11/15GAMIDA CELL : Q3 Earnings Snapshot
AQ
11/15Gamida Cell Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended S..
CI
11/15Gamida Cell Reports Third Quarter 2021 Financial Results and Provides Company Update
BU
11/12RBC Cuts Price Target on Gamida Cell to $11 From $14, Citing Setback to Omidubicel Fili..
MT
11/12Gamida Cell Provides Update on Pre-BLA Meeting with FDA for Omidubicel - Form 6-K
PU
11/12Gamida Cell Ltd Completes Type B Pre-Biologics License Application Meeting with the U.S..
CI
11/11Gamida Cell Provides Update on Pre-BLA Meeting With FDA for Omidubicel
BU
11/11Gamida Cell Provides Update on Pre-BLA Meeting With FDA for Omidubicel
CI
More news
News in other languages on GAMIDA CELL LTD.

- No features available -

More news
Analyst Recommendations on GAMIDA CELL LTD.
More recommendations
Chart GAMIDA CELL LTD.
Duration : Period :
Gamida Cell Ltd. Technical Analysis Chart | GMDA | IL0011552663 | MarketScreener
Technical analysis trends GAMIDA CELL LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 2,37 $
Average target price 14,29 $
Spread / Average Target 503%
EPS Revisions
Managers and Directors
Julian Adams Chief Executive Officer & Director
Shai Lankry Chief Financial Officer
Robert I. Blum Chairman
Ronit Simantov Chief Medical Officer
Tracey Lodie Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GAMIDA CELL LTD.-71.75%141
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
WUXI APPTEC CO., LTD.26.13%67 780
REGENERON PHARMACEUTICALS31.76%65 932
VERTEX PHARMACEUTICALS-13.26%52 122